More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...

Sep. 26, 2024 — What factors lead to chronic respiratory disease? Researchers investigated ... respiratory illnesses like asthma and pulmonary fibrosis just got easier if a new drug-carrying ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Silicosis is a long-term lung disease caused by inhaling large amounts of crystalline silica dust, usually over many years.

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H ...

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...